Mannkind Corp
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
4.53
-0.03
(-0.658%)
Volume:
6,713,872
52 week range:
1.78 - 6.25
Market Cap:
1.131B
Company Description:
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.